Saloumeh K Fischer - Concepedia

Author

Saloumeh K Fischer

Also Known As

S K Fischer, S. Fischer, Saloumeh K. Fischer, Saloumeh Fischer, Saloumeh K Fischer, Saloumeh K. Fischer, Saloumeh Kadkhodayan Fischer

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)GTx (United States)Biogen (United States)Genentech Pfizer (United States)

About

Saloumeh K Fischer is an author at Roche (Switzerland) specializing in medicine, immunology, and allergy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	742
2	Allergy	4	4	584
3	Allergy Medicine	2	2	489
4	Engineering	1	1	18
5	Natural Sciences	1	1	65

Saloumeh K Fischer

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials Nicola A. Hanania, Phillip E. Korenblat, Kenneth R. Chapman, The Lancet Respiratory Medicine AsthmaRheumatologyAllergyAllergy MedicinePharmacology	2016	463
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies Nicola A. Hanania, Michael Noonan, Jonathan Corren, Thorax	2015	374
Specific Immune Response to Phospholipase B-Like 2 Protein, a Host Cell Impurity in Lebrikizumab Clinical Material Saloumeh K Fischer, Melissa Cheu, Kun Peng, The AAPS Journal InflammationHost ResponseAutoimmune DiseasePathogenesisImmunology	2016	112
Establishment of Neurofilament Light Chain Simoa Assay in Cerebrospinal Fluid and Blood Robert L. Hendricks, Dana Baker, Jochen Brumm, Bioanalysis	2019	95
Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics Daniela Bumbaca Yadav, Vikas Sharma, C. Andrew Boswell, Journal of Biological Chemistry	2015	83
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials Amit Bar‐Or, Gian‐Andrea Thanei, Christopher Harp, EBioMedicine	2023	80
2017 White Paper on Recent Issues in Bioanalysis: A Global Perspective on Immunogenicity Guidelines & Biomarker Assay Performance (Part 3 – Lba: Immunogenicity, Biomarkers and PK Assays) Shalini Gupta, Susan Richards, Lakshmi Amaravadi, Bioanalysis ImmunohematologyPk AssaysWhite PaperImmunologyBiological Mass Spectrometry	2017	65
An<i>in vitro</i>FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans Shan Chung, Nguyễn Văn Hiệp, Yuwen Linda Lin, mAbs	2019	61
Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study Yanan Zheng, Heleen Scheerens, John C. Davis, Clinical Pharmacology & Therapeutics	2010	45
The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters Saloumeh K Fischer, Jihong Yang, Banmeet S. Anand, mAbs	2012	39

Page 1